Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II)

AVB-114 is an investigational therapy which offers a new therapeutic approach to treating this unmet medical need. The drug product is a mesenchymal cell substrate system comprised of autologous mesenchymal cells incubated with a 3-dimensional bioabsorbable substrate. The drug substance is expanded, pure mesenchymal stem cells (MSC) which are known to modulate local inflammation and orchestrate tissue healing. By incubating cells with a 3-dimensional bioabsorbable substrate designed for anal fistula geometry, cells are locally delivered into the fistula tract to promote healing.

Inclusion criteria

• Provision of signed and dated ICF.
• Ability and willingness to comply with study protocol and study requirements for the duration of the study.
• Male or female, 18-70 years of age
• Subjects with CD diagnosed at least 6 months prior to screening visit.
• Subjects with a single fistula tract with one internal opening and one external opening.
• Subjects whose perianal fistula(s) were previously treated with either biologic or conventional therapy whose fistula has demonstrated a failed response or who have documented medication intolerance.
• Women of childbearing potential (WCBP) must have negative serum pregnancy test at screening (sensitive to 25 IU human chorionic gonadotropin). WCBP participating in this study must agree to use an adequate method of contraception during the entire duration of the study. Males who have sexual partners that are women of childbearing potential must be willing to use a barrier method for contraception for the duration of study.

Exclusion criteria

• Clinically significant medical conditions within the six months before screening that would, in the opinion of the investigator, compromise the safety of the subject with study participation and/or the ability of the subject to follow study protocol.
• Evidence of hepatitis B, C, or HIV or subjects with congenital or acquired immunodeficiencies.
• Participation in an investigational drug study (within 30 days of last administration from screening visit) or investigational medical device study (within 1 year of implant from screening visit) where investigational treatment (drug or device) is placed in rectum, vagina, or near fistula location, or that may potentially interact with study treatment.
• History (within previous 5 years of screening visit) of invasive cancer including melanoma (with the exception of localized skin cancers).
• Subjects pregnant, trying to become pregnant, or are breast feeding.
• Subjects with known allergies or hypersensitivity to aminoglycosides and contraindications to Magnetic Resonance (MR) evaluations and/or to MR contrast.
• History of clinically significant fat-directed autoimmunity.
• Genito-urinary fistulization, including rectovaginal (i.e., fistulae that transverse the vaginal canal).
• Presence of an ileal anal pouch.
• Active, unresolved infection requiring parenteral antibiotics.
• Any major surgery of the gastrointestinal tract (including one or more segments of the colon or terminal ileum) within 3 months prior to screening visit. Presence of stoma is not exclusionary.
• Subjects who had a definitive surgical procedure for the target fistula or a perianal procedure that resulted in a large soft tissue defect within 6 months prior to screening visit.
• Subjects where the target adipose collection harvest site is compromised due to a previous cool sculpting procedure, local radiation, chemotherapy, recent tattoos, local infection, or other reasons that may compromise the adipose tissue for study use.
• Subjects previously treated with Cx601/Alofisel or other allogeneic or autologous stem-cell therapy within the past 6 months.
• Contraindications to the anesthetic procedure (local and general) or to the adipose tissue collection procedure.
• Subjects with one or more of the following fistula types or anatomic presentations:

• Horseshoe fistulas
• Fistulas that do not have an opening inside the anal canal or low rectum
• Blind ending sinus tracts (no external opening)
• Branching fistulas. A previously performed conversion of a branching fistula tract to a single tract is not exclusionary
• >1 internal opening
• Moderate or severe proctitis
• Severe rectal mucosal fibrosis surrounding the internal opening preventing the securing of the fistula plug cap.
• Any anatomical limitation to successfully securing the fistula plug cap
• Evidence by colonoscopy of moderately or greater active luminal CD.
• Subject with ongoing systemic or rectal steroids for CD in the last 2 weeks prior to screening and baseline study visits.
• History of, or concurrent high-grade dysplasia, adenocarcinoma, and carcinoma in situ on colonoscopy within 5 years of screening visit.
• Subjects with renal insufficiency (creatinine value > 1.8 mg/dL, eGFR < 44, or patient undergoing dialysis).
• Subjects with a hemoglobin less than 8 gm/dL.
• Subjects with serum aspartate transaminase (AST) or alanine transaminase (ALT) > 2 times the upper limit of normal (ULN).
• Subjects with an abscess within the fistula tract that cannot be resolved prior to treatment.
• Subjects with known coagulopathy (abnormal INR) or thrombocytopenia as indicated by a platelet count < 75,000.
• Subjects with history of substance abuse (drug or alcohol) that would interfere with the ability to comply with the study protocol and study requirements.